secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001193125-24-202430
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics adopts limited-duration stockholder rights plan after BML accumulates 19.3% stake
--------------------------------------------------------------------------------

- Rights plan triggered by rapid accumulation of 19.3% of ANTX common stock by BML Investment Partners, as disclosed in Aug. 14, 2024 13G/A filing.
- One preferred stock purchase right distributed per common share held on Aug. 29, 2024; exercise price $6.50 per one-thousandth of Series A Preferred.
- Rights become exercisable if a person or group acquires 20% or more of common stock (including synthetic ownership).
- Rights expire Aug. 15, 2025, unless earlier redeemed ($0.01 per right) or exchanged by Board.
- Plan designed to protect all stockholders and prevent coercive takeover tactics without paying a control premium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524202430/0001193125-24-202430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524202430/d879523d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-202430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer